- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05995353
En studie for å vurdere uønskede hendelser, endring i sykdomsaktivitet og hvordan intravenøs og subkutan risankizumab beveger seg gjennom kroppen til pediatriske deltakere med moderat til alvorlig aktiv Crohns sykdom (RISE)
En fase 3, multisenterstudie for å evaluere farmakokinetikken, effektiviteten og sikkerheten til risankizumab med åpen induksjon, randomisert dobbeltblind vedlikehold og langsiktige forlengelsesperioder hos pediatriske personer (2 til <18 år) med Moderat til alvorlig aktiv Crohns sykdom
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-post: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
-
Brussels, Belgia, 1020
- Rekruttering
- Hospital Universite Enfants Reine Fabiola /ID# 255112
-
Liège, Belgia, 4000
- Rekruttering
- Groupe Sante CHC - Clinique du MontLegia /ID# 255620
-
-
Antwerpen
-
Edegem, Antwerpen, Belgia, 2650
- Rekruttering
- Uza /Id# 255114
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgia, 1200
- Rekruttering
- Cliniques Universitaires UCL Saint-Luc /ID# 255108
-
Jette, Brussels Capital, Belgia, 1090
- Rekruttering
- Universitair Ziekenhuis Brussel /ID# 255109
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgia, 3000
- Rekruttering
- Universitair Ziekenhuis Leuven /ID# 255098
-
-
-
-
-
Plovdiv, Bulgaria, 4002
- Rekruttering
- UMHAT Sveti Georgi EAD /ID# 255386
-
Sofia, Bulgaria, 1606
- Fullført
- Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
-
Varna, Bulgaria, 9009
- Rekruttering
- UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Rekruttering
- Alberta Children's Hospital /ID# 255357
-
Edmonton, Alberta, Canada, T6G 1C9
- Rekruttering
- Edmonton Clinic Health Academy /ID# 255361
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Rekruttering
- BC Children's Hospital /ID# 255359
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Rekruttering
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85016-7710
- Rekruttering
- Phoenix Children's Hospital /ID# 255766
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72202
- Fullført
- Arkansas Children's Hospital /ID# 255762
-
-
California
-
Oakland, California, Forente stater, 94609
- Rekruttering
- UCSF Benioff Children's Hospital - Oakland /ID# 258327
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- Children's Hospital Colorado - Aurora /ID# 255764
-
-
Florida
-
Orlando, Florida, Forente stater, 32806-1141
- Rekruttering
- Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University Health Riley Hospital for Children /ID# 256454
-
-
Massachusetts
-
Waltham, Massachusetts, Forente stater, 02451
- Rekruttering
- Massachusetts General Hospital - Mass General Waltham /ID# 255767
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55413-2195
- Rekruttering
- MNGI Digestive Health, P. A. /ID# 255366
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07960
- Rekruttering
- Goryeb Childrens Hospital /ID# 256452
-
-
New York
-
New York, New York, Forente stater, 10029
- Rekruttering
- Icahn School of Medicine at Mount Sinai /ID# 254880
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland /ID# 256453
-
Ta kontakt med:
- Site Coordinator
- Telefonnummer: 216-636-2007
-
-
-
-
-
Paris, Frankrike, 75015
- Rekruttering
- AP-HP - Hopital Necker /ID# 255608
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Frankrike, 37044
- Rekruttering
- CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankrike, 33076
- Rekruttering
- Chu Bordeaux - Hopital Pellegrin /ID# 257060
-
-
Occitanie
-
Toulouse, Occitanie, Frankrike, 31059
- Rekruttering
- CHU Toulouse - Hopital Paule de Viguier /ID# 255609
-
-
Rhone
-
Bron, Rhone, Frankrike, 69500
- Rekruttering
- Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
-
-
-
-
Central District
-
Petah Tikva, Central District, Israel, 4920235
- Rekruttering
- Schneider Children's Medical Center /ID# 254950
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 91031
- Rekruttering
- Shaare Zedek Medical Center /ID# 254951
-
-
-
-
-
Messina, Italia, 98125
- Rekruttering
- Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
-
-
Genova
-
Genoa, Genova, Italia, 16147
- Rekruttering
- IRCCS Istituto Giannina Gaslini /ID# 255262
-
-
Napoli
-
Naples, Napoli, Italia, 80131
- Rekruttering
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
-
-
Roma
-
Rome, Roma, Italia, 00165
- Rekruttering
- Ospedale Pediatrico Bambino Gesu /ID# 255043
-
-
-
-
Aichi-ken
-
Ōbu, Aichi-ken, Japan, 474-8710
- Rekruttering
- Aichi Children's Health And Medical Center /ID# 272085
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-0871
- Rekruttering
- Tsujinaka Hospital - Kashiwanoha /ID# 268409
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Japan, 830-0011
- Rekruttering
- Kurume University Hospital /ID# 268418
-
-
Gunma
-
Maebashi, Gunma, Japan, 371-8511
- Rekruttering
- Gunma University Hospital /ID# 270560
-
-
Kumamoto
-
Kumamoto, Kumamoto, Japan, 861-8520
- Rekruttering
- Japanese Red Cross Kumamoto Hospital /ID# 268586
-
-
Osaka
-
Izumi-Shi, Osaka, Japan, 594-1101
- Rekruttering
- Osaka Women's and Children's Hospital /ID# 268419
-
-
Saitama
-
Saitama-shi, Saitama, Japan, 330-8777
- Rekruttering
- Saitama Children's Medical Center /ID# 268410
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8519
- Rekruttering
- Institute of Science Tokyo Hospital /ID# 269175
-
Fuchu-shi, Tokyo, Japan, 183-8561
- Rekruttering
- Tokyo Metropolitan Children's Medical Center /ID# 268415
-
Setagaya City, Tokyo, Japan, 157-8535
- Rekruttering
- National Center For Child Health And Development /ID# 268420
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100045
- Rekruttering
- Beijing Children's Hospital /ID# 256081
-
Beijing, Beijing Municipality, Kina, 100191
- Rekruttering
- Peking University Third Hospital /ID# 255876
-
Ta kontakt med:
- Site Coordinator
- Telefonnummer: +86 010-82266699
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510620
- Rekruttering
- Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
-
Guangzhou, Guangdong, Kina, 510655
- Rekruttering
- The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
-
-
Henan
-
Zhengzhou, Henan, Kina, 450018
- Rekruttering
- Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
-
-
Hunan
-
Changsha, Hunan, Kina, 410007
- Rekruttering
- Hunan Children's Hospital /ID# 255610
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Rekruttering
- Jiangxi Provincial Children's Hospital /ID# 255564
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110022
- Rekruttering
- Shengjing Hospital of China Medical University /ID# 255563
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200062
- Rekruttering
- Children's Hospital of Shanghai /ID# 255531
-
Shanghai, Shanghai Municipality, Kina, 200065
- Rekruttering
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
-
-
-
-
North Holland
-
Amsterdam, North Holland, Nederland, 1105 AZ
- Rekruttering
- Amsterdam University Medical Center /ID# 254827
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Torun, Kuyavian-Pomeranian Voivodeship, Polen, 87-100
- Fullført
- Gastromed Sp. z o.o /ID# 255939
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 04-730
- Rekruttering
- Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
-
-
-
-
-
Dorado, Puerto Rico, 00646
- Rekruttering
- Puerto Rico Health Institute /ID# 255071
-
San Juan, Puerto Rico, 00909-1711
- Rekruttering
- Clinical Research Puerto Rico /ID# 266479
-
-
-
-
-
Madrid, Spania, 28009
- Fullført
- Hospital Infantil Universitario Nino Jesus /ID# 255012
-
Málaga, Spania, 29011
- Rekruttering
- Hospital Regional Universitario de Malaga /ID# 257553
-
-
A Coruna
-
Ferrol, A Coruna, Spania, 15405
- Rekruttering
- Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
-
-
-
-
-
Birmingham, Storbritannia, B4 6NH
- Rekruttering
- Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
-
-
England
-
Sheffield, England, Storbritannia, S10 2TH
- Rekruttering
- Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
-
Ta kontakt med:
- Site Coordinator
- Telefonnummer: +44 114 273 0522
-
-
Greater London
-
London, Greater London, Storbritannia, E1 2ES
- Rekruttering
- Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
-
-
-
-
-
Bern, Sveits, 3010
- Rekruttering
- Inselspital, Universitaetsspital Bern /ID# 255321
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Sveits, 8032
- Rekruttering
- Kinderspital Zurich - Eleonorenstiftung /ID# 255337
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Sverige, 118 83
- Rekruttering
- Sodersjukhuset /ID# 255239
-
Stockholm, Stockholm County, Sverige, 171 76
- Rekruttering
- Astrid Lindgrens Barnsjukhus /ID# 255240
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Sverige, 413 46
- Rekruttering
- Sahlgrenska Universitetssjukhuset /ID# 255236
-
Ta kontakt med:
- Site Coordinator
- Telefonnummer: +46313435865
-
-
-
-
-
Daegu, Sør -Korea, 41404
- Rekruttering
- Kyungpook National University Chilgok Hospital /ID# 255817
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Sør -Korea, 03080
- Rekruttering
- Seoul National University Hospital /ID# 255318
-
Seoul, Seoul Teugbyeolsi, Sør -Korea, 06351
- Rekruttering
- Samsung Medical Center /ID# 255284
-
Seoul, Seoul Teugbyeolsi, Sør -Korea, 03722
- Rekruttering
- Yonsei University Health System - Severance Hospital /ID# 256976
-
-
-
-
-
Changhua City, Changhua County, Taiwan, 50006
- Rekruttering
- Changhua Christian Hospital /ID# 256082
-
Taipei, Taiwan, 100
- Rekruttering
- National Taiwan University Hospital /ID# 255679
-
-
-
-
Praha 17
-
Prague, Praha 17, Tsjekkia, 128 00
- Fullført
- Vseobecna Fakultni nemocnice v Praze /ID# 256096
-
-
Praha 5
-
Prague, Praha 5, Tsjekkia, 150 06
- Fullført
- Fakultni nemocnice Motol a Homolka /ID# 256547
-
-
-
-
-
Ankara, Tyrkia (Türkiye), 06560
- Rekruttering
- Gazi University Medical Faculty /ID# 255086
-
Istanbul, Tyrkia (Türkiye), 34453
- Rekruttering
- Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
-
Istanbul, Tyrkia (Türkiye), 34899
- Rekruttering
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
-
Kocaeli, Tyrkia (Türkiye), 41380
- Rekruttering
- Kocaeli University Med Faculty /ID# 256922
-
-
-
-
Bavaria
-
Munich, Bavaria, Tyskland, 80337
- Rekruttering
- Dr. von Haunerschen Kinderspital /ID# 255577
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Tyskland, 48149
- Rekruttering
- Universitaetsklinikum Muenster /ID# 256762
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Pediatric individuals, 2 to < 18 years old
- Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
- Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
- Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Exclusion Criteria:
-
History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
-
Any of the following medical disorders:
-
Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
-
A diagnosis of CD prior to 2 years of age.
-
A diagnosis or suspected diagnosis of a primary immunodeficiency.
-
Currently known complications of CD such as:
- Active abscess (abdominal or perianal);
- Symptomatic bowel strictures;
- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
- Fulminant colitis;
- Toxic megacolon;
- Or any other manifestation that might require surgery while enrolled in the study.
-
Ostomy or ileoanal pouch.
-
Diagnosis of short gut or short bowel syndrome.
-
Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.
-
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: PK Cohort 1: SS3 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 1: SS3 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 1: SS1
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 1: SS2 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 1: SS2 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
|
Eksperimentell: Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Andre navn:
Subcutaneous (SC) Injection
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Tidsramme: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Tidsramme: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Tidsramme: Up to approximately Week 64
|
Cmax of risankizumab |
Up to approximately Week 64
|
|
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Tidsramme: Up to approximately 64 weeks
|
Tmax of risankizumab |
Up to approximately 64 weeks
|
|
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Tidsramme: Up to approximately 64 weeks
|
AUCtau of risankizumab |
Up to approximately 64 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Tidsramme: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tidsramme: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Tidsramme: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Tidsramme: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tidsramme: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Tidsramme: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tidsramme: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Tidsramme: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: ABBVIE INC., AbbVie
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- M16-194
- 2022-502050-14-00 (Annen identifikator: EU CT)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Tilgangskriterier for IPD-deling
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .